Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Cryoablation in Unresectable Mesothelioma
NCT05071014Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients with an adverse event (AE) defined as any grade 3 or higher non-hematologic toxicity at 12 weeks. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NCT05071014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071014.